These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 12212929)

  • 1. Residual cell-associated unspliced HIV-1 RNA in peripheral blood of patients on potent antiretroviral therapy represents intracellular transcripts.
    Fischer M; Wong JK; Russenberger D; Joos B; Opravil M; Hirschel B; Trkola A; Kuster H; Weber R; Günthard HF;
    Antivir Ther; 2002 Jun; 7(2):91-103. PubMed ID: 12212929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human immunodeficiency virus type 1 RNA in peripheral blood mononuclear cells of patients receiving prolonged highly active antiretroviral therapy.
    Zhang J; Crumpacker CS
    J Infect Dis; 2001 Nov; 184(10):1341-4. PubMed ID: 11679927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular viral rebound after cessation of potent antiretroviral therapy predicted by levels of multiply spliced HIV-1 RNA encoding nef.
    Fischer M; Joos B; Hirschel B; Bleiber G; Weber R; Günthard HF;
    J Infect Dis; 2004 Dec; 190(11):1979-88. PubMed ID: 15529263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy.
    Furtado MR; Callaway DS; Phair JP; Kunstman KJ; Stanton JL; Macken CA; Perelson AS; Wolinsky SM
    N Engl J Med; 1999 May; 340(21):1614-22. PubMed ID: 10341273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attenuated and nonproductive viral transcription in the lymphatic tissue of HIV-1-infected patients receiving potent antiretroviral therapy.
    Fischer M; Joos B; Wong JK; Ott P; Opravil M; Hirschel B; Weber R; Günthard HF;
    J Infect Dis; 2004 Jan; 189(2):273-85. PubMed ID: 14722893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shifts in cell-associated HIV-1 RNA but not in episomal HIV-1 DNA correlate with new cycles of HIV-1 infection in vivo.
    Fischer M; Trkola A; Joos B; Hafner R; Joller H; Muesing MA; Kaufman DR; Berli E; Hirschel B; Weber R; Günthard HF;
    Antivir Ther; 2003 Apr; 8(2):97-104. PubMed ID: 12741621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of cell-free and cell-associated peripheral blood human immunodeficiency virus type 1 RNA response to antiretroviral therapy.
    Romano L; Venturi G; Catucci M; De Milito A; Valensin PE; Zazzi M
    J Infect Dis; 1999 Feb; 179(2):361-6. PubMed ID: 9878019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time.
    Ghosn J; Pellegrin I; Goujard C; Deveau C; Viard JP; Galimand J; Harzic M; Tamalet C; Meyer L; Rouzioux C; Chaix ML;
    AIDS; 2006 Jan; 20(2):159-70. PubMed ID: 16511408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human immunodeficiency virus type-1 mRNA splicing pattern in infected persons is determined by the proportion of newly infected cells.
    Vesanen M; Markowitz M; Cao Y; Ho DD; Saksela K
    Virology; 1997 Sep; 236(1):104-9. PubMed ID: 9299622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
    Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
    Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different resistance mutations can be detected simultaneously in the blood and the lung of HIV-1 infected individuals on antiretroviral therapy.
    White NC; Israel-Biet D; Coker RJ; Mitchell DM; Weber JN; Clarke JR
    J Med Virol; 2004 Mar; 72(3):352-7. PubMed ID: 14748057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of a long-term discrepancy in drug-targeted genes in plasma HIV-1 RNA and PBMC HIV-1 DNA in the same patient.
    Usuku S; Noguchi Y; Sakamoto M; Adachi T; Sagara H; Sudo K; Nishizawa M; Kondo M; Tochikubo O; Imai M
    Jpn J Infect Dis; 2006 Apr; 59(2):122-5. PubMed ID: 16632914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART.
    Chew CB; Potter SJ; Wang B; Wang YM; Shaw CO; Dwyer DE; Saksena NK
    J Clin Virol; 2005 Jul; 33(3):206-16. PubMed ID: 15911442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Both human immunodeficiency virus cellular DNA sequencing and plasma RNA sequencing are useful for detection of drug resistance mutations in blood samples from antiretroviral-drug-naive patients.
    Parisi SG; Boldrin C; Cruciani M; Nicolini G; Cerbaro I; Manfrin V; Dal Bello F; Franchin E; Franzetti M; Rossi MC; Cattelan AM; Romano L; Zazzi M; Andreoni M; Palù G
    J Clin Microbiol; 2007 Jun; 45(6):1783-8. PubMed ID: 17442799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early therapy in HIV-1-infected children: effect on HIV-1 dynamics and HIV-1-specific immune response.
    Zanchetta M; Anselmi A; Vendrame D; Rampon O; Giaquinto C; Mazza A; Accapezzato D; Barnaba V; De Rossi A
    Antivir Ther; 2008; 13(1):47-55. PubMed ID: 18389898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Depletion of mitochondrial DNA in HIV-1-infected patients and its amelioration by antiretroviral therapy.
    Miura T; Goto M; Hosoya N; Odawara T; Kitamura Y; Nakamura T; Iwamoto A
    J Med Virol; 2003 Aug; 70(4):497-505. PubMed ID: 12794710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Residual HIV-RNA levels persist for up to 2.5 years in peripheral blood mononuclear cells of patients on potent antiretroviral therapy.
    Fischer M; Günthard HF; Opravil M; Joos B; Huber W; Bisset LR; Ott P; Böni J; Weber R; Cone RW
    AIDS Res Hum Retroviruses; 2000 Aug; 16(12):1135-40. PubMed ID: 10954888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increase of HIV-1 pro-viral DNA per million peripheral blood mononuclear cells in patients with advanced HIV disease (CD4<200 cells/mm3) receiving interleukin 2 combined with HAART versus HAART alone (ANRS-082 trial).
    Delaugerre C; Gourlain K; Tubiana R; Carcelain G; Marcelin AG; Chouquet C; Mouroux M; Duvivier C; Autran B; Costagliola D; Katlama C; Calvez V
    Antivir Ther; 2003 Jun; 8(3):233-7. PubMed ID: 12924540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.